Activated Long-Term Peripheral Blood Cultures as Preparation for Adoptive Alloreactive Cell Therapy in Cancer Patients
- 1 April 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Hematotherapy
- Vol. 6 (2) , 115-124
- https://doi.org/10.1089/scd.1.1997.6.115
Abstract
Different modes of in vitro activation of peripheral blood mononuclear cells (PBMC) were compared for their effect on long-term propagation. PBMC cultures were activated by short exposures to the mitogen phytohemagglutinin (PHA) and the CD3 complex, with or without secondary signals provided by ligands of CD28 costimulatory molecules. Activation and long-term cultures were carried out in the presence of recombinant interleukin-2 (rIL-2). Addition of supernatant derived from IL-2-activated PBMC improved culture cell yield. Cumulative fold expansions ranged between 103 and 105 within 21 days. The highest cell yield was found after PHA activation. Fewer cells were obtained after activation with a combination of CD3 and CD28, and even fewer were obtained after CD3 activation alone. An increase in CD8+ and CD56+ cells, without change in CD4+ cells, was found in activated cultures when compared with fresh PBMC. Non-MHC-restricted cytotoxic activity was documented in all activated cultures. Cytotoxic activity per culture was highest in PHA-activated PBMC because of the high cell yield on the day of harvest. Successful in vitro expansion of PBMC might be helpful for gene transfer into T lymphocytes, as well as for the induction of an antitumor response, particularly for prevention and treatment of relapse of hematologic malignancies following allogeneic or autologous bone marrow transplantation.Keywords
This publication has 23 references indexed in Scilit:
- PRECLINICAL STUDIES FOR ADOPTIVE IMMUNOTHERAPY IN BONE MARROW TRANSPLANTATIONTransplantation, 1993
- Signal transduction events leading to T-cell lymphokine gene expressionImmunology Today, 1993
- Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2Cancer Immunology, Immunotherapy, 1992
- Tumor-infiltrating lymphocytes from nonrenal urological malignanciesCancer Immunology, Immunotherapy, 1990
- Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodiesCancer Immunology, Immunotherapy, 1990
- Cellular Immune Response Against Autologous Human Malignant Melanoma: Are In Vitro Studies Providing a Framework for a More Effective Immunotherapy?JNCI Journal of the National Cancer Institute, 1990
- Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatantsCancer Immunology, Immunotherapy, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Lymphokine-activated killer cell activity: Characteristics of effector cells and their progenitors in blood and spleenImmunology Today, 1987
- Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated LymphocytesAnnual Review of Immunology, 1986